Abstract: Methods for detecting an infection with Mycobacterium tuberculosis (Mtb) in a subject are disclosed, wherein the subject is a child, a subject with a latent Mycobacterium tuberculosis infection. Method are also disclose for detecting an extra-pulmonary Mycobacterium tuberculosis infection in a subject. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample.

Abstract: The present invention relates to methods and kits for diagnosing systemic inflammatory response syndrome or sepsis using levels of FSTL-1.

Abstract: The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to anti-bodies for the diagnosis or condition, especially cancer.

Abstract: Assays are disclosed for diagnosing a clinical condition, assessing risk or predicting an outcome as a result of cardiac myocyte damage. Immunoassay methods and kits provide for the assessment of cardiac myocyte damage by determining the presence of multiple cardiac myocyte antigens in a test sample, and combining the multiple determinations in a single assay result.

Abstract: The present invention relates to a method and kit for the isolation of cells from a sample. The sample is treated with an extraction solution that comprises at least MgCl2 and/or an ionic liquid resulting in the isolation of preferably viable cells.

Abstract: The present invention relates to methods and polypeptides for detecting a compound in a sample. In particular, the present invention relates to the use of a cell-free composition comprising at least one G protein coupled receptor embedded in a lipid Mayer which when expressed in a cell the N-terminus of the G protein coupled receptor, or subunits thereof, is outside the cell and the C-terminus is inside the cell, and which is capable of binding the compound. Optionally, the composition also comprises at least one accessory molecule that directly or indirectly binds an intracellular loop and/or the C-terminus of the G protein coupled receptor. The G protein coupled receptor, and/or accessory molecule when present, in combination comprise a bioluminescent protein and an acceptor molecule, which enables bioluminescent resonance energy transfer (BRET) to be used to detect the compound binding the receptor.

Abstract: The invention is based on the finding that IDT307 and analogs thereof are fluorescent substrates transported by several neurotransmitter transporters. Provided are methods for the analysis of neurotransmitter transport and binding using IDT307 and its analogs. The invention also provides rapid methods for screening for modulators of neurotransmitter transport.

Abstract: A method and apparatus for delivering one or more fluids. Fluids may be delivered sequentially from a common vessel to a chemical, biological or biochemical process.

Abstract: A versatile drug testing device (a lateral flow diagnostic testing device) includes a flat transparent carrier with a top and a bottom with the carrier having a series of independent parallel grooves formed therein running from adjacent to the top to adjacent to the bottom of the carrier, each groove having a first opening and a second opening above the first opening therein adjacent to the bottom of the carrier, at least one drug test strip installed in one of said grooves with its absorbent pad contiguous to the openings and a cover layer attached to the carrier operable to sealing close each of said grooves whereby the bottom of the device can be immersed in a specimen of urine, body fluid, or other biological specimen to wet the pad of the at least one test strip though the ingress of the specimen though the associated openings and the test results on the test strip can be easily viewed through the transparent carrier.

Abstract: Methods, devices, systems, and apparatuses are provided for the image analysis of measurement of biological samples.

Abstract: A screening method for identifying compounds with anti-emetic properties by evaluating binding affinity and efficacy of the compounds with respect to the 5-HT1a, 5-HT1d, and 5-HT7 receptors.

Abstract: The invention relates to the identification of carboxylic acids, present in human sweat, as natural ligands of a specific subgroup of seven olfactory receptor (OR) belonging to class 1 within the OR classification. The invention encompasses the use of the interaction of OR polypeptides and carboxylic acids as the basis of screening assays for agents that specifically modulate the activity of the seven ORs of the invention.

Abstract: The present invention, provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus.

Abstract: The invention relates to a method for optimizing the automatic fluorescence pattern recognition in immunodiagnosis. In this method, in addition to or together with the fluorescence dye, one or more other indicator dyes for the identification of relevant structures are incubated before an image is taken with a camera.

Abstract: The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control features, to provide flow control information, to function as an internal control and/or to provide internal calibration information for the test device. The present invention also relates to methods for using the lateral flow devices to provide flow control information, to function as an internal control and/or to provide internal calibration information for the test device.

Abstract: A method of measuring binding between hemoglobin and a microbe of interest includes: providing hemoglobin from a source of interest; contacting the hemoglobin with a microbe of interest; and measuring the binding affinity between the hemoglobin and the microbe, wherein the binding affinity is indicative of microbe virulence in the presence of the hemoglobin.

Abstract: Disclosed is a method for a rapid test. In accordance with an embodiment, a particle reagent is placed into a separate sample or reagent receptacle or test tube, in which the particle reagent reacts with one or several analytes in the liquid sample, and the particle reagent is put into contact with the rapid test device, in which a visible signal is formed by the particle reagent.

Abstract: This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.

Abstract: Three-dimensional microfluidic devices including by a plurality of patterned porous, hydrophilic layers and a fluid-impermeable layer disposed between every two adjacent patterned porous, hydrophilic layers are described. Each patterned porous, hydrophilic layer has a fluid-impermeable barrier which substantially permeates the thickness of the porous, hydrophilic layer and defines boundaries of one or more hydrophilic regions within the patterned porous, hydrophilic layer. The fluid-impermeable layer has openings which are aligned with at least part of the hydrophilic region within at least one adjacent patterned porous, hydrophilic layer. Microfluidic assay device, microfluidic mixer, microfluidic flow control device are also described.

Abstract: The present invention relates to functional, modified glucose-galactose binding proteins (GGBPs), that have a greater melting temperature (Tm) than a reference GGBP. The present invention also relates to biological sensors, e.g., glucose sensors, comprising these thermostable GGBPs. The present invention also relates to nucleic acids encoding these thermostable GGBPs.

Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.

Abstract: The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents.

Abstract: Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and treat ICAM-1-related pathological conditions.

Abstract: The invention pertains to a disposable cartridge suitable for use in detecting the presence of analytes in fluid samples. The cartridge is designed to provide “lab on a chip” capabilities and comprises a plurality of sample storage reservoirs and analytical compartments/channels. A valve system based on valve disks aids in securely transferring samples from storage reservoirs to analytical channels and detectors with minimal use of common channels, which reduces risk of cross-contamination.

Abstract: The present invention features a method for identifying an agent that inhibits Candida albicans-mediated differentiation of keratinocytes. Agents identified by the screening assay of the invention find application in the prevention and treatment of candidiasis.

Abstract: Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.

Abstract: The invention is directed to ?1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The ?1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The ?1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated ?1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.

Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.

Abstract: [Problems] To provide a marker which is useful in diagnosing leukemia and a method of using the same. [Means for Solving Problems] A method of detecting a leukemia cell which comprises detecting a CD34-positive cell being negative in DOCK180 expression from a blood specimen. According to this method, a DOCK180 expression pattern specific to a tumor cell in leukemia, in particular, acute leukemia is confirmed so that information which is useful in diagnosing leukemia and monitoring and determining the severity and degree of recovery of the same by a doctor can be obtained by a convenient procedure using blood specimens and thus provided.

Abstract: There is described a system for testing a sample. The system comprises a microplate, at least one actuator, a plurality of mutually spaced sensors, and a processor. The microplate has a test portion including an interactive substance. The interactive substance is inherently interactive with a specified test substance. The microplate is arranged such that at least the test portion of the microplate may be brought into contact with the sample. The at least one actuator is operable to vibrate the microplate. The plurality of mutually spaced sensors are coupled to the microplate. Each sensor is operable to provide a respective sensory data time series during vibration of the microplate. The microplate and the sensors are arranged such that the provided sensory data time series are not independent from one another.

Abstract: The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided.

Abstract: This invention provides substrates for use in various applications, including single-molecule analytical reactions. Methods for propagating optical energy within a substrate are provided. Devices comprising waveguide substrates and dielectric omnidirectional reflectors are provided. Waveguide substrates with improved uniformity of optical energy intensity across one or more waveguides and enhanced waveguide illumination efficiency within an analytic detection region of the arrays are provided.

Abstract: Sandwich separation is based on forming a sandwich complex with a magnetic bead, buoyant bead, and a target. Once a sandwich formation is created, the sandwich can be separated using its dual physical properties, namely magnetism and buoyancy. Sandwich separation is highly specific, allows for removal of the beads that do not have any attached target, and reduces the number of background beads. Sandwich separation can also be used to allow for target detection in raw specimen. Also, improvement of detection capability is accomplished by performing AMBR measurements on a solid interface, where the rotational period speeds up and allows for dramatically reduced time-to-result.

Abstract: A process for detecting cells from a sample, comprising the following steps: (a) applying the sample or a fraction of the sample in liquid phase in a direction of flow to a porous, generally two-dimensional support with pores having on the surface thereof at least one binding molecule specific for the cells to be detected or for fragments of such cells; (b) allowing the cells to be detected or of fragments of such cells to enter from the sample or sample fraction into the pores of said porous, generally two-dimensional support, said pores having such a mean pore size that the cells or fragments to be detected are able to enter into the pores; (c) retaining the cells or fragments to be detected by at least one binding molecule specific for the cells or fragments to be detected; (d) performing an optical read-out method on said substantially two-dimensional support by an imaging method, optionally after the cells or cell fragments to be detected have been labeled with a labeling agent; wherein (e) the optica

Abstract: Provided is a bio-disc reading apparatus for reading information including product authentication of a bio-disc and assay site of a bio-disc, and an assay method using same.

Abstract: The invention intends to find out an in-vitro bioassay system capable of ensuring qualities of yokukansan to a higher degree, and provides a bioassay method for yokukansan, comprising competitively reacting labeled ligand and a test sample containing yokukansan with cells or cell membranes expressing serotonin 1A receptors, and measuring binding activity of yokukansan from the amount of the labeled ligand bound, and a bioassay method for yokukansan, comprising reacting labeled GTP and a test sample containing yokukansan with cells or cell membranes expressing serotonin 1A receptors, and measuring receptor-agonist activity of yokukansan from the amount of the labeled GTP bound.

Abstract: The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.

Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.

Abstract: The present disclosure relates to biophotonic sensors. An example of a biophotonic sensor may be an apparatus for analyzing a sample. The apparatus may include a substrate, aperiodic nanostructured protrusions disposed on the substrate, and a silk material deposited between the protrusions.

Abstract: A lateral flow device for use in a mainframe or point-of-care clinical analyzer, in which the lateral flow device includes a planar support having at least one sample addition area and at least one reaction area disposed thereon. The sample addition area and reaction area are fluidly interconnected to one another and form at least one lateral fluid flow path. The lateral flow device is sized for retention within a storage cartridge of the analyzer defined by a hollow interior and having a plurality of lateral flow assay devices retained in stacked relation therein.

Abstract: The present invention relates to pH-tunable, highly activatable multicolored fluorescent nanoplatforms and methods of using the nanoplatforms in a variety of applications including, but not limited to, investigating fundamental cell physiological processes such as pH regulation in endocytic vesicles, endosome/lysosome maturation, and effect of pH on receptor cycling and trafficking of subcellular organelles.

Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.

Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins, nucleic acids and cellular organelles. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified to provide beneficial properties.

Abstract: The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints.

Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli.

Abstract: Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.

Abstract: The invention relates to the identification of a novel epitope on non-functional P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.

Abstract: Provided is a method for determining immunoglobulins in a neonatal ungulate. The method entails obtaining a sample of oral secretions from the neonatal ungulate and measuring an amount of immunoglobulins in the sample of oral secretions. The method is faster and more convenient than previously available methods for determining immunglobulins in neonatal ungulates, such as neonatal horses and cattle.

Abstract: A full process control for use with a molecular assay and a method of determine the efficacy of the molecular assay. A full process control can include a fixed cell, and specifically can include a fixed vegetative cell. A method of determining the efficacy of a molecular assay can include providing an internal control, mixing the internal control with a sample, lysing the internal control and the sample, and detecting the lysis product. The full process control and/or the internal control can be Bacillus subtilis cells.

Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.